Recombinant Rsv Antigens

Patent No. EP3109258 (titled "Recombinant Rsv Antigens") was filed by Glaxosmithkline on Dec 23, 2008. The application was issued on Jan 23, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JANSSEN VACCINES & PREVENTIONOct 23, 2019MEWBURN ELLIS
PFIZEROct 23, 2019PFIZER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3109258

GLAXOSMITHKLINE
Application Number
EP16180926A
Filing Date
Dec 23, 2008
Status
Revoked
Dec 1, 2023
Publication Date
Jan 23, 2019